Detalles de la búsqueda
1.
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Cell
; 170(6): 1109-1119.e10, 2017 Sep 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28886381
2.
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Cell
; 174(4): 1031-1032, 2018 08 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30096300
3.
Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
Jpn J Clin Oncol
; 44(5): 442-7, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24782485
4.
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
Lancet Oncol
; 14(3): 228-35, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23414585
5.
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
J Clin Oncol
; 41(3): 528-540, 2023 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35998300
6.
KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.
Am J Ther
; 16(6): 554-61, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19352138
7.
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
J Clin Oncol
; 36(17): 1658-1667, 2018 06 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28981385
8.
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
J Clin Oncol
; 33(25): 2780-8, 2015 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26014293
9.
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.
Clin Cancer Res
; 20(16): 4240-50, 2014 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24919569
10.
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
Clin Cancer Res
; 19(15): 4282-9, 2013 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23741071
11.
Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer.
Clin Cancer Res
; 16(7): 2205-13, 2010 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20332321
12.
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
J Clin Oncol
; 28(31): 4706-13, 2010 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20921462
13.
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
J Clin Oncol
; 28(31): 4697-705, 2010 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20921465
14.
Human NKT cells express granulysin and exhibit antimycobacterial activity.
J Immunol
; 170(6): 3154-61, 2003 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12626573
Resultados
1 -
14
de 14
1
Próxima >
>>